Web notes  
October 2013
PUBLICATIONS - Back

Oncology
[Oncology archives]

1. Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013.
Key words: mesenchymal, microenvironment, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23975882

2. Di Cello F, Flowers VL, Li H, Vecchio-Pagán B, Gordon B, Harbom K, Shin J, Beaty R, Wang W, Brayton C, Baylin SB, Zahnow CA. Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. Mol Cancer. 2013 Aug 6;12:90. doi: 10.1186/1476-4598-12-90.
Key words: smoke, mesenchymal, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/23919753

3. Fu C, van der Zwan A, Gerber S, Van Den Berg S, No E, C H Wang W, Sheibani N, Carducci MA, Kachhap S, Hammers HJ. Screening assay for blood vessel maturation inhibitors. Biochem Biophys Res Commun. 2013 Aug 23;438(2):364-9. doi: 10.1016/j.bbrc.2013.07.077. Epub 2013 Jul 25.
Key words: inhibitor, blood vessel, maturation
http://www.ncbi.nlm.nih.gov/pubmed/23892038

4. Fuchs EJ. Selective allodepletion: have we finally found the holy grail? Biol Blood Marrow Transplant. 2013 Aug 13. doi:pii: S1083-8791(13)00353-4. 10.1016/j.bbmt.2013.08.004. [Epub ahead of print]
Key words: allodepletion, holy grail
http://www.ncbi.nlm.nih.gov/pubmed/23954761

5. Murray-Stewart T, Hanigan CL, Woster PM, Marton LJ, Casero RA. Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism. Mol Cancer Ther. 2013 Aug 13. [Epub ahead of print]
Key words: miRNA, deacetylase, inhibition
http://www.ncbi.nlm.nih.gov/pubmed/23943804

6. Rangachari D, Brahmer JR. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol. 2013 Aug 11. [Epub ahead of print]
Key words: lung cancer, immune, targeting
http://www.ncbi.nlm.nih.gov/pubmed/23934510

7. Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer. 2013 Aug 13. doi: 10.1002/cncr.28270. [Epub ahead of print]
Key words: docetaxel, prostate cancer, leuprolide
http://www.ncbi.nlm.nih.gov/pubmed/23943299

8. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA. Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2013 Aug 20. doi: 10.1038/pcan.2013.28. [Epub ahead of print]
Key words: disulfiram, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/23958896

9. Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma. 2013 Aug 28. [Epub ahead of print]
Key words: myelodysplastic, infection, bleeding
http://www.ncbi.nlm.nih.gov/pubmed/23841504

10. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15;133(4):997-1005. doi: 10.1002/ijc.28083. Epub 2013 Mar 4.
Key words: temsirolimus, doxorubicin, sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/23382028

11. Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, Vogelstein B, Zhou S. A nanoparticle formulation that selectively transfects metastatic tumors in mice. Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14717-22. doi: 10.1073/pnas.1313330110. Epub 2013 Aug 19.
Key words: nanoparticle, mice, tumors
http://www.ncbi.nlm.nih.gov/pubmed/23959886

12. Zeidan AM, Gore SD, McNally DL, Baer MR, Hendrick F, Mahmoud D, Davidoff AJ. Lenalidomide
performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes. Cancer. 2013 Aug 6. doi: 10.1002/cncr.28298. [Epub ahead of print]
Key words: myelodysplastic, lenalidomide
http://www.ncbi.nlm.nih.gov/pubmed/23922173


Return to top of Publications - Oncology

Search Publications
 
   
October 2013 articles:
New Version of HIPAA Combined Informed Consent Authorization Template
 
Visit Animal Care and Use Committee Website
Current Classes
Dean's Research Integrity Lectures
Funding from Foundations/Private Sources
2014 NIH Director's Early Independence Awards

This Month's Departmental Listings

Upcoming Deadlines for October, November and December

       

 

JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 

 

                                                                                                                                                           The Web Center